A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial
Citations
1 citations
Journal
Blood
Topics
Chronic Lymphocytic Leukemia Research
Field-Weighted Citation Impact (FWCI)
1.63
article
A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
BloodVol. 146(Supplement 1)
Institutions
AstraZeneca (United Kingdom) (GB), Medical University of Lublin (PL), The Royal Melbourne Hospital (AU), University of Debrecen (HU), University of Ottawa (CA), Peter MacCallum Cancer Centre (AU), Institut Gustave Roussy (FR), Centre Hospitalier Universitaire de Montpellier (FR), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Levine Cancer Institute (US), San Francisco Public Library (US), Center for Cancer and Blood Disorders (US), Dana-Farber Cancer Institute (US), Amsterdam University Medical Centers (NL), The Catholic University of Korea Seoul St. Mary's Hospital (KR), Lublin University of Technology (PL)